Answers are grounded in this paper and cite their sources.
Ovarian cancer recurrence is a challenging clinical situation. Systemic treatment has been the standard of care in this group of patients; however, its survival benefit remains unclear. Since the publication of the DESKTOP III trial, cytoreductive surgery has also been considered for selected
No takes yet. Share an insight, caveat, or question.
Rychlik et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: